S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
NASDAQ:APOP

Cellect Biotechnology Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$13.17
+0.05 (+0.38%)
(As of 12/31/1969)
Add
Compare
Today's Range
$13.10
$13.37
50-Day Range
$7.54
$13.40
52-Week Range
$6.64
$35.52
Volume
17,400 shs
Average Volume
479,845 shs
Market Capitalization
$12.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.87

Receive APOP News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellect Biotechnology and its competitors with MarketBeat's FREE daily newsletter.


Cellect Biotechnology logo

About Cellect Biotechnology

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

Headlines

Cellect Biotechnology (NASDAQ:APOP) Stock Price Up 0.4%
November 20, 2021 |  americanbankingnews.com
Why Cellect Biotechnology Shares Are Rising Today
September 27, 2021 |  benzinga.com
Pre-market Movers: APOP, FBRX, ANY, AGIL, ADXS…
September 3, 2021 |  markets.businessinsider.com
Cellect Registers Merger Agreement
June 17, 2021 |  baystreet.ca
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APOP
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.77 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$12.87 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/13/2018
Today
12/02/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

0.96 out of 5 stars

Medical Sector

1270th out of 1,391 stocks

Surgical & Medical Instruments Industry

121st out of 126 stocks

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Cellect Biotechnology (NASDAQ:APOP) Frequently Asked Questions

How were Cellect Biotechnology's earnings last quarter?

Cellect Biotechnology Ltd. (NASDAQ:APOP) released its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.02.
View Cellect Biotechnology's earnings history
.

When did Cellect Biotechnology's stock split? How did Cellect Biotechnology's stock split work?

Shares of Cellect Biotechnology split before market open on Tuesday, October 26th 2021. The 2-1 split was announced on Tuesday, October 26th 2021. The newly minted shares were distributed to shareholders after the market closes on Tuesday, October 26th 2021. An investor that had 100 shares of Cellect Biotechnology stock prior to the split would have 200 shares after the split.

Who are Cellect Biotechnology's key executives?

Cellect Biotechnology's management team includes the following people:
  • Shai Yarkoni, Chief Executive Officer & Director
  • Amos Ofer, Chief Operating Officer
  • Yaron Ben-Oz, Chief Financial Officer

What other stocks do shareholders of Cellect Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellect Biotechnology investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Protalix BioTherapeutics (PLX), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Acasti Pharma (ACST), Allergan (AGN), Novavax (NVAX) and RedHill Biopharma (RDHL).

What is Cellect Biotechnology's stock symbol?

Cellect Biotechnology trades on the NASDAQ under the ticker symbol "APOP."

Who are Cellect Biotechnology's major shareholders?

Cellect Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.71%) and Geode Capital Management LLC (1.33%).

Which major investors are selling Cellect Biotechnology stock?

APOP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

Which major investors are buying Cellect Biotechnology stock?

APOP stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC.

What is Cellect Biotechnology's stock price today?

One share of APOP stock can currently be purchased for approximately $13.17.

How much money does Cellect Biotechnology make?

Cellect Biotechnology has a market capitalization of $12.87 million.

How many employees does Cellect Biotechnology have?

Cellect Biotechnology employs 2,020 workers across the globe.

What is Cellect Biotechnology's official website?

The official website for Cellect Biotechnology is www.cellect.co.

Where are Cellect Biotechnology's headquarters?

Cellect Biotechnology is headquartered at 23 HATA`AS STREET, KFAR SABA L3, 44425.

How can I contact Cellect Biotechnology?

Cellect Biotechnology's mailing address is 23 HATA`AS STREET, KFAR SABA L3, 44425. The company can be reached via phone at (729) 974-1444, via email at [email protected], or via fax at 972-9767-8750.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.